argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

argenx commenced a tender offer to buy all outstanding Forte Biosciences shares for $77.00 per share in cash (net to seller), with settlement targeted shortly after acceptance (no later than the first business day after the Aug. 26, 2026 expiration). The deal is structured to close via a merger without a Forte stockholder vote under DGCL Section 251(h), subject to tender/antitrust conditions and without a financing condition. Forte shareholders are being recommended to accept, implying a near-term positive catalyst for FBRX and M&A sentiment for the biopharma space.

Analysis

This is more signal than size: for ARGX, the main equity reaction channel is not earnings accretion but credibility. Paying cash for a small, mechanistically adjacent autoimmune asset tells the market management is willing to use balance-sheet strength to fill pipeline gaps rather than wait for de-risked internal data, which should modestly support the multiple on the “platform + optionality” story. The nearer-term beneficiary is the target’s holders via arb; the real loser is any competing early-stage CD122/autoimmune program that was hoping scarcity would keep acquisition multiples low.

Second-order, this can lift implied takeout value across the small-cap immunology cohort, especially single-asset names with clean mechanistic narratives and low burn. That said, the deal is too small to force broad rerating of large-cap biopharma; the key implication is that strategic buyers with approved franchises and cash generation may be willing to pay up for platform adjacency before Phase 2 proof, which matters for XBI constituents more than for mega-caps.

Risk is almost entirely deal-completion over the next 2-4 weeks: HSR, tender mechanics, and any last-minute competing bid are the only meaningful catalysts. Over 1-3 months, the relevant question is whether ARGX uses this as a template for more pipeline M&A; if not, the market may fade the signal. The contrarian view is that this is not a broad M&A thaw, just a routine tuck-in, so any rally in the sector beyond arb names may be overdone unless a second transaction follows quickly.

Key Decisions for Investors

• Long FBRX only as merger-arb, but size it off the remaining discount to $77 and annualized spread; if the stock trades within ~1-2% of cash value, the risk/reward is poor and better left alone.
• If the spread widens materially on HSR or financing headlines, buy FBRX against a short in XBI or IBB as a hedge only for idiosyncratic deal risk; the thesis is completion, not biotech beta.
• Watch ARGX as a sentiment proxy for cash-rich immunology M&A. If management follows with a second tuck-in over the next 3-6 months, that is the signal to add a basket long in quality autoimmune platform names; absent that, fade any sector rerating.
• For event-driven desks, use a hard stop on FBRX if the deal-implied downside reopens by more than ~5% versus cash value, which would indicate market-implied break risk is rising faster than the calendar is decaying.